Genetic Modification

T cells play a vital role in cell-mediated immunity, Creative Biolabs offers strategies to genetically modify T cells either through altering the specificity of the T cell receptor (TCR) or through introducing antibody-like recognition in chimeric antigen receptor (CAR). TCR design construction and CAR design construction, both are based on genetic modification technology.

Transgenic cells: gene sequences are transferred into T cells encoding new TCR alpha and beta chains with different peptide specificity. In addition, transmembrane changes may occur (red bars). To minimize mismatches with endogenous TCR chains, some modifications were made, such as the addition of a disulfide bridge (ss).

Fig.1 Blueprint of CAR/TCR structure. Left to right: the designs of TCR-T cell.¹

Gene modification in the clinical treatment of TCR:

In vitro screening strategies are employed to reduce the risk that antigens targeted by a modified TCR also arise in vital organs.

• Myeloma
• Melanoma
• Metastatic colorectal cancer
• Metastatic colon cancer

Ability to provide four possible TCR specificity receptors between natural and transgenic cell.

• Endogenous alpha and beta TCR
• Genetically modified alpha and beta TCR
• Genetically modified alpha, endogenous beta TCR
• Endogenous alpha genetically modified beta TCR

Manufacturing and delivery pipeline of genetically modified T-cell therapies

• Obtain T cells from patients under Good Manufacturing Practices (GMP) manufacturing facilities to provide you with quality assured raw materials for cell genetic engineering.
• Able to provide patent-approved receptors based on antibody recognition sequences (chimeric antigen receptors (CAR)).
• Transparent genetically modified T-Cell product offered for your tumor treatment.
• Perfect regulatory guidance of FDA standards is available on the requirements for preclinical testing.

• Provide you with the best quality products, all products comply with ISO9001 international quality management system.
• Our scientific research team creates the most professional service for you.
• Build the most favorable after-sales service system platform.
• Committed to the development of new products, research and technology, to help your scientific research in accordance with the international advanced level synchronization.

Please contact us and our team will get back to you as soon as possible.

Reference

1. Zhu, Yu-Ge, et al. "Genetically modified T cells for esophageal cancer therapy: A promising clinical application." Frontiers in Oncology 11 (2021): 763806.

For Research Use Only | Not For Clinical Use

Resources

Download our brochure